StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$27.52−0.28 (-1.01%)

Close on Nov 17, 2026Market cap $3.07BP/E –Yield –

Amylyx Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Amylyx Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$126.58M. For fiscal 2025 it was -$123.34M. The highest annual figure on record is $11.92M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$123.34M–
FY2024Dec 31, 2024-$167.65M-1506.6%
FY2023Dec 31, 2023$11.92M–
FY2022Dec 31, 2022-$179.87M–
FY2021Dec 31, 2021-$74.80M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.42M–
Q1 FY2026Mar 31, 2026-$36.88M–
Q4 FY2025Dec 31, 2025-$27.90M–
Q3 FY2025Sep 30, 2025-$30.37M–
Q2 FY2025Jun 30, 2025-$25.25M–
Q1 FY2025Mar 31, 2025-$39.82M–
Q4 FY2024Dec 31, 2024-$59.01M-535.5%
Q3 FY2024Sep 30, 2024-$41.57M–
Q2 FY2024Jun 30, 2024-$66.58M-873.4%
Q1 FY2024Mar 31, 2024-$489.00K–
Q4 FY2023Dec 31, 2023$13.55M–
Q3 FY2023Sep 30, 2023-$5.17M–
Q2 FY2023Jun 30, 2023$8.61M–
Q1 FY2023Mar 31, 2023-$5.07M–
Q4 FY2022Dec 31, 2022-$49.70M–
Q3 FY2022Sep 30, 2022-$43.08M–
Q2 FY2022Jun 30, 2022-$46.46M–
Q1 FY2022Mar 31, 2022-$40.63M–
Q4 FY2021Dec 31, 2021-$28.24M–
Q3 FY2021Sep 30, 2021-$20.87M–
Q2 FY2021Jun 30, 2021-$13.05M–
Q1 FY2021Mar 31, 2021-$12.64M–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?